on behalf of the PX-171-003-A1 study investigatorsJohn Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey
Carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc, South San Francisco, CA) is a selective proteasome inhibitor that irreversibly binds to active sites within the proteolytic core of the 26S proteasome, resulting in inhibition of proteasome activity. Preclinical studies have shown carfilzomib inhibits tumor growth and promotes tumor cell death, with sustained proteasome inhibition for more than 48 hours when using a consecutive-day dosing regimen.1-4
To sign up for our newsletter or print publications, please enter your contact information below.